Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
The taxes are part of the president's push to rein in the pharmaceutical industry and bring manufacturing to the U.S.
Summary
President Trump's announcement of 100% tariffs on brand-name drugs is a significant policy shift aimed at the pharmaceutical industry. This move is part of a broader strategy to reduce dependency on foreign manufacturing.
The tariffs are expected to have substantial implications for the supply chain and pricing structures within the pharmaceutical sector. Companies may need to reassess their production strategies to mitigate the impact of these tariffs.
While the announcement includes various carveouts, the overall effect could lead to increased costs for consumers and healthcare providers, as manufacturers adjust to the new economic landscape.
Key Facts
| Fact | Value |
|---|---|
| Primary source | STAT |
| Source count | 2 |
| First published | 2026-04-02T19:31:01.000Z |
Updates
Update at 13:26 UTC on 2026-04-03
STAT reported Significant caveats accompany the new tariffs as discussions on a U.S.-U.K. pharma trade deal continue.
Sources: STAT